Lancet infectious diseases study compare well with Phase 3 clinical trials of COVAXIN: Bharat Biotech


Content Team
Image Credit: Shortpdia

Commenting on the study of the Lancet Infectious Diseases on the effectiveness of COVAXIN (BBV152) against symptomatic RT-PCR, the Hyderabad-based Bharat Biotech has said that the results compare well with 65.2 per cent efficacy against Delta variant obtained during controlled phase 3 clinical trials of COVAXIN conducted among the general population.